In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.
The ACC issued new guidance for managing common pediatric left-to-right shunts, including ASD, VSD, and PDA, in the ...
PHI Air Medical, a leading U.S. helicopter-based medical transport provider, today proudly announces that its Cedar Creek base is setting the gold standard in emergency medical care across Central ...
Nationally, there has been a rise in the number of children and adolescents with congenital and acquired heart disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results